Imperial reports voting results for election of directors
CALGARY, Alberta--(BUSINESS WIRE)-- Imperial Oil Limited (TSE: IMO, NYSE American: IMO) announced at its annual meeting of shareholders held on May 3, 2022, that each of the seven nominees proposed as directors of the company and listed in its management proxy circular dated March 16, 2022 were elected as directors. A total of 606,381,191 shares (90.62 percent of outstanding common shares) were represented in person or by proxy. The percentage of shares represented at the meeting that were voted to elect the individual directors are set out below:
Nominee: |
For: |
Withheld: |
||
D.W. (David) Cornhill |
540,497,248 |
|
61,434,933 |
|
B.W. (Bradley) Corson |
586,247,361 |
|
15,684,820 |
|
M.R. (Matthew) Crocker |
577,063,393 |
|
24,868,788 |
|
K.T. (Krystyna) Hoeg |
590,765,513 |
|
11,166,118 |
|
M.C. (Miranda) Hubbs |
596,301,725 |
|
5,630,456 |
|
J.M. (Jack) Mintz |
580,745,526 |
|
21,186,655 |
|
D.S. (David) Sutherland |
586,743,639 |
|
15,188,158 |
After more than a century, Imperial continues to be an industry leader in applying technology and innovation to responsibly develop Canada’s energy resources. As Canada’s largest petroleum refiner, a major producer of crude oil, a key petrochemical producer and a leading fuels marketer from coast to coast, our company remains committed to high standards across all areas of our business.
Source: Imperial
View source version on businesswire.com: https://www.businesswire.com/news/home/20220503006317/en/
Investor relations
(587) 476-4743
Media relations
(587) 476-7010
Source: Imperial
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
- Binance Acquires BTEXCHAIN, Accelerating the Integration of AI and Global Digital Asset Trading Technology
- The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Crude OilSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share